Drug, Biologics and Combination Products Labeling – Webinar Recording/Transcript
Want to attend the live webinar on Dec. 8? Click here to register.
The FDA guidance on Instructions for Use (IFU) aims to make labeling of prescription drugs, biologics and combination products clearer and more helpful to patients. But this could have implications for your business’ new drug applications (NDAs) and biologics license applications (BLAs).
If you’re unsure how to proceed, you’re not alone. In this webinar, Alan G. Minsk, Esq. — a Partner and Leader of the Food & Drug Practice Team of Arnall Golden Gregory LLP — will clarify the guidance and explain how to comply with it, focusing on the issues you must consider as you implement changes to your IFUs.
- Why FDA issued the draft guidance and its importance to regulatory, quality and compliance specialists, including the content and format concerns of FDA in general and details necessary for safe and effective use
- What kind of language IFUs should be written in to be patient friendly
- What the guidance recommends in terms of voice, commands and sentences
- Examples of sample labeling that covers all elements of an IFU from dosage and usage to storage and disposal
- What kinds of recommendations FDA makes in terms of design and layout, such as the use of easy-to-read fonts, sequential numbering and white space
- Some practical considerations on patient labeling, from a business perspective
If you are at all unclear how to implement this guidance and change your IFUs to include what FDA considers to be “clear, concise information that is easily understood,” you must attend this presentation. Your NDAs and BLAs depend on it. Join us by registering today.
Meet Your Presenter
Alan G. Minsk, Esq. is a Partner and Leader of the Food & Drug Practice Team of Arnall Golden Gregory LLP, an Am Law 200 law firm located in Atlanta, Georgia and Washington, D.C. He advises pharmaceutical, biologic, medical device, cosmetic and food companies (including dietary supplements and medical foods) on all legal and regulatory matters relating to the U.S. Food and Drug Administration. Mr. Minsk counsels clients on a wide variety of FDA-related issues including regulatory strategies and life cycle management, combination products, FDA enforcement, FDA inspections, compliance, market exclusivity, product promotion and advertising, clinical trials and imports and exports. Mr. Minsk conducts in-house training on FDA topics.
Who Will Benefit
- Regulatory Affairs Professionals
- Quality Assurance Professionals
- Marketing Professionals
Webinar Recording & Transcript Bundle
Add to Cart
Nov. 13, 2020